ICU Medical reported second quarter 2025 revenue of $548.9 million, a decrease from $596.5 million in the prior year. Despite the revenue decline, the company achieved a GAAP net income of $35.3 million, a substantial improvement from a net loss in Q2 2024. Adjusted diluted EPS also saw a notable increase to $2.10.

ICU Medical reported improved results in the first quarter of 2025 compared to the prior year, with increased total revenues, gross profit, and a significantly reduced net loss. Adjusted EBITDA and adjusted diluted EPS also showed strong growth.

ICU Medical's Q4 2024 revenue rose to $629.8 million, reflecting strong demand across all segments, particularly in Vital Care. However, the company posted a GAAP net loss of $23.8 million, with an EPS of $(0.97), impacted by increased operating expenses. Adjusted EPS improved to $2.11, and adjusted EBITDA grew to $105.5 million, driven by better gross margins and higher revenue.

ICU Medical announced third quarter 2024 results with revenue of $589.1 million, compared to $553.3 million in the same period last year. GAAP net loss was $(33.0) million, or $(1.35) per diluted share. Adjusted diluted earnings per share was $1.59, compared to $1.57 for the third quarter of 2023. The company updated its fiscal year 2024 guidance for GAAP net loss and adjusted EBITDA.

ICU Medical reported second quarter revenue of $596.5 million, compared to $549.3 million in the same period in the prior year. GAAP net loss for the second quarter of 2024 was $(21.4) million, or $(0.88) per diluted share. Adjusted diluted earnings per share for the second quarter of 2024 was $1.56.

ICU Medical reported first quarter revenue of $566.7 million, a slight decrease compared to $568.6 million in the same period last year. The company's GAAP net loss was $(39.5) million, or $(1.63) per diluted share, compared to a net loss of $(9.8) million, or $(0.41) per diluted share, for the first quarter of 2023. Adjusted diluted earnings per share were $0.96, down from $1.74 in the prior year.

ICU Medical reported Q4 2023 revenue of $587.9 million, a slight increase from $578.0 million in the same period last year. The company's GAAP net loss was $(17.1) million, or $(0.71) per diluted share, compared to a net loss of $(15.5) million, or $(0.65) per diluted share, for the fourth quarter of 2022. Adjusted diluted earnings per share for the fourth quarter of 2023 was $1.57 as compared to $1.60 for the fourth quarter of 2022. Adjusted EBITDA was $86.3 million for the fourth quarter of 2023 as compared to $96.4 million for the fourth quarter of 2022.

ICU Medical announced third quarter 2023 financial results with revenue of $553.3 million, compared to $597.9 million in the same period last year. GAAP net income was $7.2 million, or $0.30 per diluted share, compared to a GAAP net loss of $(13.2) million, or $(0.55) per diluted share, for the third quarter of 2022. Adjusted diluted earnings per share was $1.57 as compared to $1.75 for the third quarter of 2022.

ICU Medical reported second quarter revenue of $549.3 million, a decrease compared to $561.0 million in the same period last year. The company's GAAP gross profit increased to $192.3 million from $167.6 million, with a gross margin of 35% compared to 30% last year. GAAP net loss was $(9.9) million, or $(0.41) per diluted share, while adjusted diluted earnings per share was $1.88. Adjusted EBITDA was $98.1 million, compared to $84.7 million in the same quarter of the previous year.

ICU Medical reported first quarter 2023 revenue of $568.6 million, a gross profit of $192.0 million, and a net loss of $(9.8) million, or $(0.41) per diluted share. Adjusted diluted earnings per share was $1.74, and adjusted EBITDA was $102.0 million.

ICU Medical's fourth quarter 2022 revenue was $578.0 million, compared to $340.5 million in the same period last year. The adjusted diluted earnings per share for the fourth quarter of 2022 was $1.60 as compared to $1.82 for the fourth quarter of 2021.

ICU Medical announced third quarter 2022 results with revenue of $597.9 million, GAAP gross profit of $186.4 million, and a GAAP net loss of $(13.2) million, or $(0.55) per diluted share. Adjusted diluted earnings per share was $1.75, and adjusted EBITDA was $92.6 million. The company reaffirmed its full year 2022 guidance but expects to end the fiscal year towards the lower end of the guidance range due to the impact primarily from foreign currency exchange rates.

ICU Medical's second quarter 2022 revenue was $561.0 million, compared to $321.7 million in the same period last year. GAAP net loss for the second quarter of 2022 was $(7.5) million, or $(0.31) per diluted share. The company updated its full year 2022 guidance of adjusted EBITDA from a range of $450 million to $500 million to a range of $350 million to $370 million and adjusted diluted earnings per share from a range of $9.00 to $10.50 to a range of $6.20 to $6.80.

ICU Medical's first quarter 2022 revenue was $543.1 million, a significant increase from $318.0 million in the same period last year, primarily due to the acquisition of Smiths Medical. However, the company reported a GAAP net loss of $(38.1) million, or $(1.61) per diluted share, compared to a net income of $23.7 million, or $1.09 per diluted share, for the first quarter of 2021.

ICU Medical reported Q4 2021 revenue of $340.5 million, compared to $320.5 million in the same period last year. GAAP net income for the fourth quarter of 2021 was $19.9 million, or $0.91 per diluted share, as compared to GAAP net income of $26.1 million, or $1.21 per diluted share, for the fourth quarter of 2020.

ICU Medical announced financial results for the quarter ended September 30, 2021, with revenue of $336.1 million, GAAP gross profit of $127.8 million, and GAAP net income of $31.1 million, or $1.43 per diluted share.

ICU Medical announced its second quarter 2021 results, with revenue reaching $321.7 million compared to $303.4 million in the same period last year. GAAP net income was $28.4 million, or $1.31 per diluted share, compared to $18.9 million, or $0.88 per diluted share, for the second quarter of 2020. The company updated its full year 2021 guidance for adjusted EBITDA and adjusted diluted earnings per share.

ICU Medical reported first quarter 2021 results with revenue of $318.0 million, a decrease compared to $328.6 million in the same period last year. GAAP net income was $23.7 million, or $1.09 per diluted share, compared to $16.8 million, or $0.78 per diluted share, for the first quarter of 2020. Adjusted diluted earnings per share were $1.62, as compared to $1.81 for the first quarter of 2020.

ICU Medical, Inc. reported fourth quarter revenue of $320.5 million, compared to $315.5 million in the same period last year. GAAP net income for the fourth quarter of 2020 was $26.1 million, or $1.21 per diluted share, as compared to GAAP net income of $20.6 million, or $0.96 per diluted share, for the fourth quarter of 2019.

ICU Medical, Inc. reported third quarter revenue of $318.6 million, compared to $307.5 million in the same period last year. GAAP net income for the third quarter of 2020 was $25.0 million, or $1.16 per diluted share, as compared to GAAP net income of $26.6 million, or $1.24 per diluted share, for the third quarter of 2019.

ICU Medical announced second-quarter revenue of $303.4 million, compared to $312.3 million in the same period last year. GAAP net income was $18.9 million, or $0.88 per diluted share, as compared to GAAP net income of $22.8 million, or $1.06 per diluted share, for the second quarter of 2019.

ICU Medical reported first quarter 2020 revenue of $328.6 million, a decrease compared to $330.9 million in the same period last year. GAAP net income was $16.8 million, or $0.78 per diluted share, compared to $31.0 million, or $1.44 per diluted share, for the first quarter of 2019. Adjusted diluted earnings per share were $1.81, compared to $2.58 for the first quarter of 2019. Adjusted EBITDA was $63.0 million, compared to $77.9 million for the first quarter of 2019.

ICU Medical reported a revenue of $315.5 million for Q4 2019, a decrease from $340.4 million in Q4 2018. However, the company's net income increased to $20.6 million, or $0.96 per diluted share, compared to a net loss of $7.4 million, or $0.36 loss per diluted share, in the same period last year. Adjusted diluted earnings per share were $1.94, and adjusted EBITDA was $60.7 million.